Opendata, web and dolomites

RIGVIR

Feasibility study for registration of medicine RIGVIR with the European Medicine Agency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RIGVIR" data sheet

The following table provides information about the project.

Coordinator
SABIEDRIBA AR IEROBEZOTU ATBILDIBU LATIMA 

Organization address
address: TEATRA IELA 9 - 7
city: RIGA
postcode: LV-1050
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Latvia [LV]
 Project website http://rigvir.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SABIEDRIBA AR IEROBEZOTU ATBILDIBU LATIMA LV (RIGA) coordinator 50˙000.00

Map

 Project objective

Cancer is one of the most dangerous life-threatening disorders for humanity of which melanoma is considered to be one of the most dangerous and aggressive. There are a number of therapies available to treat melanoma. However, these treatments are generally marginally effective and very expensive.

Latima SIA develops and produces Rigvir® for virotherapy. Rigvir® is a unique anti-cancer medicine using non-pathogenic virus. It has been demonstrated to be very effective in treating various cancers, and has a promising medical future . RIGVIR is commercialised in Latvia, Georgia and Armenia. Rigvir® was approved and registered in Latvia in 2004 and has since been a front-line treatment for melanoma in Latvia. However,further use and commercialisation in the EU is prevented as EU regulations require cancer medicines to be registered centrally through the European Medicine Agency (EMA). National registrations are not considered. Therefore, the process for European Union registration must be started de novo. Registration of a medicinal product requires significant costs and resources. The purpose of this H2020-SMEInst-2016-2017 application is to secure the financial support for an initial feasibility study that would provide the basis for subsequent clinical trials necessary for the registration of Rigvir® with the EMA.

It is expected that after feasibility study we would continue with next phase of H2020-SMEInst-2016-2017 and perform the clinical trials necessary for registration in EMA.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RIGVIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RIGVIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More